よむ、つかう、まなぶ。

MC plus(エムシープラス)は、診療報酬・介護報酬改定関連のニュース、

資料、研修などをパッケージした総合メディアです。


11【参考資料1-6】9価HPVワクチンファクトシート (42 ページ)

公開元URL https://www.mhlw.go.jp/stf/newpage_29181.html
出典情報 厚生科学審議会予防接種・ワクチン分科会(第41回 11/18)《厚生労働省》
低解像度画像をダウンロード

資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。

1624

https://www.ncbi.nlm.nih.gov/pubmed/28541571

1660

to 2017. BMC Infect Dis 20(1): 297.

1625

29. 国⽴がん研究センター がん情報サービス.(2020). 全国がん罹患データ(2016 年-2017

1661

42. Orumaa, M., et al. (2020). The impact of HPV multi-cohort vaccination: Real-world

1626

年) cancer_incidenceNCR(2016-2017).xls.

1662

evidence of faster control of HPV-related morbidity. Vaccine 38(6): 1345-1351.

1627

https://ganjoho.jp/reg_stat/statistics/dl/index.html

1663

43. 国⽴がん研究センター「がん情報サービス」
.全国がん死亡データ(1958 年-2018 年)

1628

30. 国⽴がん研究センター がん対策情報センター.(2018).「がん登録・統計」⼩児・AYA

1664

cancer_mortality(1958-2018).xls.https://ganjoho.jp/reg_stat/statistics/dl/index.html

1629

世代のがんの罹患率.https://ganjoho.jp/reg_stat/statistics/stat/child_aya.html

1665

44. WHO (2019). Cancer Mortality Database

1630

31. Jung, K. W., et al. (2019). Cancer Statistics in Korea: Incidence, Mortality, Survival, and

1666

https://www-dep.iarc.fr/WHOdb/WHOdb.htm

1631

Prevalence in 2016. Cancer Res Treat 51(2): 417-430.

1667

45.

1632

https://www.ncbi.nlm.nih.gov/pubmed/30913865

1668

Screening Program in Korea: A Retrospective Observational Study. Asian Nurs Res (Korean
Soc Nurs Sci) 12(1): 9-16. https://www.ncbi.nlm.nih.gov/pubmed/29463482

Lee, J. H., et al. (2018). Contributions and Limitations of National Cervical Cancer

1633

32. Cancer Incidence in Five Continents Time Trends, I., WHO (2018). NPCR: National

1669

1634

Program of Cancer Registries. https://ci5.iarc.fr/CI5plus/Default.aspx

1670

46. Smith, M. and K. Canfell (2016). Impact of the Australian National Cervical Screening

1635

33. 国⽴がん研究センター がん情報サービス. (2020).全国推計値:がん罹患データ(1975

1671

Program in women of different ages. Med J Aust 205(8): 359-364.

1636

年-2015 年)cancer_incidence(1975-2015).xls

1672

https://www.ncbi.nlm.nih.gov/pubmed/27736623

1637

https://ganjoho.jp/reg_stat/statistics/dl/index.html

1673

47. 公益財団法⼈ がん研究振興財団. (2020)がん統計'19.

1638

34.

Saito, T., et al. (2017). Annual Report of the Committee on Gynecologic Oncology,

1674

https://www.fpcr.or.jp/data_files/view/41/mode:inline

1639

Japan Society of Obstetrics and Gynecology: Patient Annual Report for 2014 and Treatment

1675

48. Van Doorslaer, K., et al. (2017). The Papillomavirus Episteme: a major update to the

1640

Annual Report for 2009. J Obstet Gynaecol Res 43(11): 1667-1677.

1676

papillomavirus

1641

https://www.ncbi.nlm.nih.gov/pubmed/28892220

1677

https://www.ncbi.nlm.nih.gov/pubmed/28053164

1642

35. 厚⽣労働省 国⽴感染症研究所. (2020).感染症週報 2020 年第 42 週・50 週.通巻第 22

1678

49.

1643

巻第 42 号・50 号.

1679

cancer progression: a comprehensive review. Clin Sci (Lond) 131(17): 2201-2221.

sequence

database.

Nucleic

Acids

Res

45(D1):

D499-D506.

Graham, S. V. (2017). The human papillomavirus replication cycle, and its links to

1644

https://www.niid.go.jp/niid/images/idsc/idwr/IDWR2020/idwr2020-42.pdf

1680

https://www.ncbi.nlm.nih.gov/pubmed/28798073

1645

https://www.niid.go.jp/niid/images/idsc/idwr/IDWR2020/idwr2020-50.pdf

1681

50. Cobos, C., et al. (2014). The role of human papilloma virus (HPV) infection in non-

1646

36. Kawado, M., et al. (2020). Estimating nationwide cases of sexually transmitted diseases

1682

anogenital cancer and the promise of immunotherapy: a review. Int Rev Immunol 33(5): 383-

1647

in 2015 from sentinel surveillance data in Japan. BMC Infect Dis 20(1): 77.

1683

401. https://www.ncbi.nlm.nih.gov/pubmed/24811210

1648

37.

Drolet, M., et al. (2019). Population-level impact and herd effects following the

1684

51. Brianti, P., et al. (2017). Review of HPV-related diseases and cancers. New Microbiol

1649

introduction of human papillomavirus vaccination programmes: updated systematic review

1685

40(2): 80-85. https://www.ncbi.nlm.nih.gov/pubmed/28368072

1650

and meta-analysis. Lancet 394(10197): 497-509.

1686

52.

1651

38.

Shing, J. Z., et al. (2019). Trends in anogenital wart incidence among Tennessee

1687

States, 2012-2016. MMWR Morb Mortal Wkly Rep 68(33): 724-728

1652

Medicaid enrollees, 2006-2014: The impact of human papillomavirus vaccination.

1688

53.

1653

Papillomavirus Res 7: 141-149.

1689

cancers - United States, 2004-2008. MMWR Morb Mortal Wkly Rep 61: 258-261.

1654

39. Stanley, M. (2014). HPV vaccination in boys and men. Hum Vaccin Immunother 10(7):

1690

https://www.ncbi.nlm.nih.gov/pubmed/22513527

1655

2109-2111.

1691

54. Clifford, G. M., et al. (2005). Human papillomavirus genotype distribution in low-grade

1656

40. Al-Awadhi, R., et al. (2019). Association of HPV genotypes with external anogenital

1692

cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol

1657

warts: a cross sectional study. BMC Infect Dis 19(1): 375.

1693

Biomarkers Prev 14(5): 1157-1164. https://www.ncbi.nlm.nih.gov/pubmed/15894666

1658

41. Reuschenbach, M., et al. (2020). Burden of HPV related anogenital diseases in young

1694

55. X. Castellsague, S. d. S., T. Aguado, K.S. Louie, L. Bruni, J. Munoz, M. Diaz, K. Irwin,

1659

women in Germany - an analysis of German statutory health insurance claims data from 2012

1695

M. Gacic, O. Beauvais, G. Albero, E. Ferrer, S. Byrne, F.X. Bosch (2007). SECTION I.

83

Senkomago, V., et al. (2019). Human Papillomavirus-Attributable Cancers - United
Centers for Disease, C. and Prevention (2012). Human papillomavirus-associated

84